Apreo Health, based in Menlo Park, California, emerged from stealth with promising first-in-human clinical results for its Breathe airway scaffold, designed to relieve pressure in overinflated lungs without removing healthy tissue. The device targets severe emphysema and lung hyperinflation, conditions with limited treatment options.
The BREATHE 1&2 feasibility studies enrolled 60 patients across Australia and Europe. Findings will be presented at the American Thoracic Society 2025 International Conference. Apreo aims to offer a broadly applicable, non-destructive treatment for emphysema patients underserved by current therapies, advancing to its next clinical phase.
Follow MEDWIRE.AI for respiratory innovation updates.
